

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 -9. (Canceled)

10. (Currently Amended) The method of claim 38, wherein β -lapachone [[,] and imatinib are administered intravenously, orally or intraperitoneally.

11. (Currently Amended) The method of claim 38, wherein β -lapachone[[,] and imatinib are administered orally.

12. (Currently Amended) The method of claim 38, wherein imatinib is administered orally.

13. (Previously presented) The method of claim 38, wherein β -lapachone is administered intravenously.

14. (Previously presented) The method of claim 38, wherein imatinib is administered simultaneously with, preceding administration of, or following administration of β -lapachone.

15. (Previously presented) The method of claim 14, wherein imatinib is administered following administration of β -lapachone.

16. (Previously presented) The method of claim 15, wherein imatinib is administered within 24 hours after β -lapachone is administered.

17. (Currently Amended) The method of claim 38, wherein the therapeutically effective amount of β -lapachone[[,] is contained in a first vial, and imatinib is contained in a second vial, the contents of the first and second vials being administered to the patient simultaneously or sequentially.

18 -21. (Canceled)

22. (Previously presented) The method of claim 38, wherein imatinib is administered at a dosage of approximately 400, 600 or 800 mg/day.
23. (Previously presented) The method of claim 38, wherein β -lapachone is administered at a dosage from about 100 to 500,000 μg per kilogram body weight of recipient per day.
24. (Previously presented) The method of claim 38, wherein β -lapachone is administered at a dosage from about 1000 to 250,000 μg per kilogram body weight of recipient per day.
25. (Previously presented) The method of claim 38, wherein β -lapachone is administered at a dosage from about 10,000 to 150,000 μg per kilogram body weight of recipient per day.
26. (Previously presented) The method of claim 38, wherein β -lapachone is administered at a dosage from about 2 mg/m^2 to 5000 mg/m^2 per day.
27. (Previously presented) The method of claim 38, wherein β -lapachone at a dosage from about 20 mg/m^2 to 500 mg/m^2 per day.
28. (Previously presented) The method of claim 38, wherein β -lapachone is administered at a dosage from about 30 to 300 mg/m^2 per day.
29. (Currently Amended) The method of claim 38, wherein β -lapachone[[,]] further comprises a pharmaceutically acceptable carrier.
30. (Previously presented) The method of claim 29, wherein the pharmaceutically acceptable carrier is a water solubilizing carrier molecule selected from the group consisting of Poloxamer, Povidone K17, Povidone K12, Tween 80, ethanol, Cremophor/ethanol, polyethylene glycol (PEG) 400, propylene glycol, Trappsol, alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin.
31. (Previously presented) The method of claim 38, wherein the subject is human.

32 - 37. (Canceled)

38. (Currently amended) A method of treating multiple myeloma in a human, the method comprising administering to the subject a therapeutically effective amount of β -lapachone[[,] and imatinib, such that the multiple myeloma is treated.

39. (Canceled)